Zydus, XOMA enter into licensing agreement for IL-2-Based Immuno-Oncology Therapy Medical Dialogues Bureau11 March 2020 9:00 AM ISTAhmedabad, Emeryville: Zydus Cadila and XOMA Corporation have announced they have entered into a licensing agreement to advance an IL-2-based...
AstraZeneca fails to meet target endpoints in Phase II bladder cancer trial Medical Dialogues Bureau10 March 2020 9:30 AM ISTUSA: The Phase III DANUBE trial for Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer did not...
AbbVie gets positive CHMP Opinion for VENCLYXTO for Leukemia patients Medical Dialogues Bureau8 Feb 2020 10:00 AM ISTNew Delhi: AbbVie , a research-based global biopharmaceutical company, announced recently that the Committee for Medicinal Products for Human Use...
Shilpa Medicare launches breakthrough therapy lenvatinib mesylate under brand Lenshil in India MD bureau3 Feb 2020 1:22 PM IST Shilpa Medicare shall launch lenvatinib, at a breakthrough price which is over 50% lower than the existing brand available in India. Prior to the...
Roche provides update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer MD bureau27 Jan 2020 2:22 PM ISTBasel: Roche has announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy...
Johnson & Johnson misses revenue estimates as blockbuster drugs disappoint Medical Dialogues Bureau24 Jan 2020 2:02 PM ISTUS: Johnson & Johnson narrowly missed quarterly revenue estimates on Wednesday as sales of its blockbuster psoriasis medicine Stelara and cancer...
Drugmajors slash prices by 53pc for China bulk-buy program eligibility Medical Dialogues Bureau20 Jan 2020 10:00 AM ISTBeijing: Global pharmaceutical majors and generic drugmakers chopped by 53% on average prices of some of their off-patent products in the latest...
ProBioGen, Lava Therapeutics ink agreement for Novel Bispecific Molecule Medical Dialogues Bureau20 Jan 2020 9:45 AM ISTNew Delhi: ProBioGen AG and Lava Therapeutics B.V. announced the closing of a cell line development and manufacturing agreement for Lava's novel...
Tecentriq-Avastin cocktail helps liver cancer patients live longer: Roche Medical Dialogues Bureau25 Nov 2019 9:00 AM ISTMedian overall survival for patients with unresectable hepatocellular carcinoma (HCC), or that which cannot be surgically removed, getting Tecentriq...
AstraZeneca leukemia drug Calquence gets USFDA okay Medical Dialogues Bureau24 Nov 2019 10:00 AM ISTNew Delhi: AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go-ahead for the company's Calquence drug...
FIRST: Roche wins DCGI nod for Atezolizumab to treat small-cell lung cancer Medical Dialogues Bureau22 Nov 2019 12:25 PM IST"Atezolizumab is the first cancer immunotherapy to receive approval from DCGI in India for the first-line treatment of extensive-stage small-cell lung...
BeiGene gets USFDA approval for lymphoma drug Brukinsa Medical Dialogues Bureau17 Nov 2019 9:20 AM ISTBeiGene tested the treatment, Brukinsa, in 118 patients with mantle cell lymphoma enrolled in two studies. About three-quarters were Asian, 21%...
